You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

EBV-Positive Lymphoma

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Hodgkin Disease, Non-Hodgkin Lymphoma, Severe Chronic Active Epstein Barr Virus Trial in Houston (MABEL CTLs, Cyclophosphamide,

Recruiting
  • Hodgkin Disease
  • +5 more
  • MABEL CTLs
  • +2 more
  • Houston, Texas
  • +1 more
Jan 13, 2023

Hodgkin's Disease, Non-Hodgkin's Lymphoma, Lymphoproliferative Disease Trial in Houston (EBV-specific T cells: A, EBV-specific T

Recruiting
  • Hodgkin's Disease
  • +3 more
  • EBV-specific T cells: A
  • EBV-specific T cells: B
  • Houston, Texas
  • +1 more
Jun 28, 2022

PD-1 Antibody, Hemophagocytic Lymphohistiocytosis, Epstein-Barr Virus Trial in Beijing (L-DEP and PD-1 antibody)

Not yet recruiting
  • PD-1 Antibody
  • +3 more
  • L-DEP and PD-1 antibody
  • Beijing, Beijing, China
    Beijing Friendship Hospital, Capital Medical University
Mar 8, 2023

EBV-Related Hodgkin Lymphoma, Lymphoproliferative Disorders, EBV Related Non-Hodgkin's Lymphoma Trial in Houston (Dose Level 1A:

Not yet recruiting
  • EBV-Related Hodgkin Lymphoma
  • +2 more
  • Dose Level 1A: 2 x 10^7 cells/m2
  • +4 more
  • Houston, Texas
  • +1 more
Feb 7, 2022

Epstein-Barr Virus Infections, Lymphoma, Lymphoproliferative Disorder Trial run by the NCI (Nivolumab)

Recruiting
  • Epstein-Barr Virus Infections
  • +3 more
  • Nivolumab
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 24, 2023

EBV-Positive DLBCL, Nos Trial in Guangzhou, Shanghai (Selinexor, R-CHOP Protocol)

Recruiting
  • EBV-Positive Diffuse Large B-Cell Lymphoma, Nos
  • Guangzhou, Guangdong, China
  • +1 more
Nov 10, 2022

NonHodgkin Lymphoma, Lymphoproliferative Disorders, EBV Related Lymphoma Trial in Houston (EBVST Cells, Nivolumab)

Completed
  • NonHodgkin Lymphoma
  • +6 more
  • EBVST Cells
  • Nivolumab
  • Houston, Texas
  • +1 more
Jul 19, 2021

Extranodal NK/T-cell Lymphoma Trial in Korea, Republic of (VT-EBV-N, Placebo)

Recruiting
  • Extranodal NK/T-cell Lymphoma
  • VT-EBV-N
  • Placebo
  • Busan, Korea, Republic of
  • +7 more
Apr 28, 2022

Lymphoma, Hodgkin's Disease, Relapse Trial in Houston (TGFbeta resistant LMP-specific CTLs)

Active, not recruiting
  • Lymphoma
  • +3 more
  • TGFbeta resistant LMP-specific CTLs
  • Houston, Texas
  • +1 more
Dec 8, 2021

EBV Associated Extranodal NK/T-cell Lymphoma, EBV-Associated GastricCarcinoma or Esophageal AdenoCarcinoma Trial in Korea,

Recruiting
  • EBV Associated Extranodal NK/T-cell Lymphoma
  • EBV-Associated GastricCarcinoma or Esophageal AdenoCarcinoma
  • EBViNT Cell
  • Seoul, Gangnam-gu, Korea, Republic of
  • +7 more
Jul 7, 2022

Epstein-Barr Virus Associated Lymphoproliferative Disorder, EBV-Related PTLD, EBV Related Non-Hodgkin's Lymphoma Trial in

Recruiting
  • Epstein-Barr Virus Associated Lymphoproliferative Disorder
  • +7 more
  • Nanatinostat in combination with valganciclovir
  • Birmingham, Alabama
  • +57 more
Aug 10, 2022

Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma Grade IIIb Trial in Guangzhou (Toripalimab,

Recruiting
  • Diffuse Large B Cell Lymphoma
  • +5 more
  • Toripalimab, Rituximab
  • R-CHOP Protocol
  • Guangzhou, Guangdong, China
    Department of hematology department, Nanfang hospital
Apr 6, 2022

Mature B-Cell Tumor, Non Hodgkin Lymphoma, DLBCL Trial (SGR-1505)

Not yet recruiting
  • Mature B-Cell Neoplasm
  • +25 more
  • (no location specified)
Sep 14, 2022

Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma, Aggressive B-cell NHL Trial in Boston

Not yet recruiting
  • Refractory Aggressive B-cell Lymphomas
  • +12 more
  • Boston, Massachusetts
  • +1 more
Oct 13, 2022

Recurrent ALK Positive Large B-Cell Lymphoma, Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between

Not yet recruiting
  • Recurrent ALK Positive Large B-Cell Lymphoma
  • +28 more
  • Biospecimen Collection
  • +5 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Aug 17, 2022

T-cell Lymphoma, NK-Cell Lymphoma, T-cell Prolymphocytic Leukemia Trial in United States (Optional Blood Sample, Optional Nail

Recruiting
  • T-cell Lymphoma
  • +30 more
  • Optional Blood Sample
  • Optional Nail Sample
  • Duarte, California
  • +25 more
Jul 28, 2023

Aggressive Non-Hodgkin Lymphoma, ALK-Positive Large B-Cell Lymphoma, B-Cell Lymphoma, Unclassifiable, With Features Intermediate

Recruiting
  • Aggressive Non-Hodgkin Lymphoma
  • +8 more
  • Polatuzumab Vedotin
  • +6 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jan 26, 2023

Primary Mediastinal Large B Cell Lymphoma, EBV-Positive DLBCL, Nos Trial in Shanghai (Zanubrutinib, Tislelizumab)

Recruiting
  • Primary Mediastinal Large B Cell Lymphoma
  • EBV-Positive DLBCL, Nos
  • Shanghai, Shanghai, China
    Ruijin Hospital
Mar 29, 2021

NK-T-Cell Lymphoma, Extranodal Trial in Shanghai (4 cycles of ESA regimen with sandwiched radiotherapy, 2 cycles of ESA regimen

Not yet recruiting
  • NK-T-Cell Lymphoma, Extranodal
  • 4 cycles of ESA regimen with sandwiched radiotherapy
  • +2 more
  • Shanghai, Shanghai, China
    Ruijin Hospital
Sep 29, 2023

LGLL - Large Granular Lymphocytic Leukemia, Primary Cutaneous T-Cell Lymphoma - Category, Primary Cutaneous CD8-Positive

Recruiting
  • LGLL - Large Granular Lymphocytic Leukemia
  • +13 more
  • Duarte, California
  • +9 more
Aug 9, 2022

ALK-Positive Large B-Cell Lymphoma, Burkitt-Like Lymphoma With 11q Aberration, DLBCL Activated B-Cell Type Trial in United

Active, not recruiting
  • ALK-Positive Large B-Cell Lymphoma
  • +34 more
  • Phoenix, Arizona
  • +32 more
Jan 3, 2023

Malignant Tumor Trial in Chendu (EBV immunological agent)

Recruiting
  • Malignant Tumor
  • EBV immunological agent
  • Chendu, Sichuan, China
    West China Hospital
Jan 31, 2023

Hodgkin Disease, Non Hodgkin Lymphoma, Lymphoepithelioma Trial in Houston (LMP1/2 CTLs (ALCI - Group A), LMP1/2 CTLs (ALCI -

Completed
Has Results
  • Hodgkin Disease
  • +3 more
  • LMP1/2 CTLs (ALCI - Group A)
  • +8 more
  • Houston, Texas
  • +1 more
May 26, 2020

Malignant Tumors Trial in Chengdu (EBV mRNA vaccine)

Recruiting
  • Malignant Tumors
  • EBV mRNA vaccine
  • Chengdu, Sichuan, China
    West China Hospital, Sichuan University
Jan 27, 2023

EBV Lymphoma, Post-transplant Lymphoproliferative Disease (PTLD) Trial in Switzerland (Donor-derived ex-vivo expanded EBV Tscm

Not yet recruiting
  • EBV Lymphoma
  • Post-transplant Lymphoproliferative Disease (PTLD)
  • Donor-derived ex-vivo expanded EBV Tscm CTL
  • Basel, Switzerland
  • +7 more
Jan 25, 2023